logo

For the Inventor, By the Inventor

London, United Kingdom

Laurent Jean Martin Rigoreau

This inventor holds 12 USPTO granted patents and 2 EPO patents. Top assignees: Cancer Research Technology Limited, Kudos Pharmaceuticals Limited. Active years: 2006-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laurent Jean Martin Rigoreau. Retrieved from https://idiyas.com/inventor/laurent-jean-martin-rigoreau

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 12

% Patents Active = 25.0

 

Average Co-Inventor Count = 7.6

ph-index = 4

Forward Citations = 51(Granted Patents)


Location History:

  • Horsham, GB (2006 - 2008)
  • Sussex, GB (2006 - 2010)
  • London, GB (2008 - 2017)

Company Filing History:

goldMedal9 out of 269 
 
Cancer Research Technology Limited
 patents
silverMedal5 out of 36 
 
Kudos Pharmaceuticals Limited
 patents
where one patent can have more than one assignee

Years Active: 2006-2017

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 9771362 - [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use (2017-09-26),
2. 9394301 - [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use (2016-07-19),
3. 9012633 - [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use (2015-04-21),
4. 8431596 - [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use (2013-04-30),
5. 7732483 - DNA-PK inhibitors (2010-06-08),
6. 7674823 - DNA-PK inhibitors (2010-03-09),
7. 7642254 - ATM inhibitors (2010-01-05),
8. 7429660 - ATM inhibitors (2008-09-30),
9. 7402607 - DNA-PK inhibitors (2008-07-22),
10. 7226918 - DNA-PK inhibitors (2007-06-05),
11. 7105518 - Thiopyrane-4-ones as DNA protein kinase inhibitors (2006-09-12),
12. 7049313 - ATM inhibitors (2006-05-23),

Title: Innovations and Contributions of Laurent Jean Martin Rigoreau

Introduction

Laurent Jean Martin Rigoreau is a prominent inventor based in London, GB. He has made significant contributions to the field of therapeutic compounds, particularly in the development of triazolo compounds. With a total of 12 patents to his name, Rigoreau's work has the potential to impact the treatment of various diseases, including cancer.

Latest Patents

Rigoreau's latest patents focus on [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds. These compounds are designed to inhibit AXL receptor tyrosine kinase function, which plays a crucial role in several proliferative conditions. The inventions also include pharmaceutical compositions that utilize these compounds for both in vitro and in vivo applications, aiming to treat diseases mediated by AXL receptor tyrosine kinase.

Career Highlights

Throughout his career, Laurent Jean Martin Rigoreau has worked with notable organizations such as Cancer Research Technology Limited and Kudos Pharmaceuticals Limited. His expertise in therapeutic compounds has positioned him as a key figure in the pharmaceutical industry, contributing to advancements in cancer treatment.

Collaborations

Rigoreau has collaborated with esteemed colleagues, including Graeme Cameron Murray Smith and Niall Morrison Barr Martin. These partnerships have fostered

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…